When good transforming growth factor-β turns bad in hepatocellular carcinoma: Axl takes the stage

Hepatology

Volumn 61, Issue 3, 2015, Pages 759-761

  Calvisi, Diego F ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXL KINASE; BGB 324; DIETHYLNITROSAMINE; DP 3975; GALUNISERTIB; GELATINASE B; NA 80X1; PROTEIN KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCAFFOLD PROTEIN; SGI 7079; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; TOSYLARGININE METHYL ESTER; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR PROMOTER; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; ONCOPROTEIN;

ALPHA FETOPROTEIN BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INCIDENCE; CANCER INHIBITION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE PROGRESSION; CELL DEATH; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL POLARITY; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; EPITHELIAL MESENCHYMAL TRANSITION; FOLLOW UP; GENE OVEREXPRESSION; HEPATOMA CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; METASTASIS; MICROARRAY ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RODENT; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; TUMOR RECURRENCE; UPREGULATION; AUTOCRINE EFFECT; FEMALE; LIVER TUMOR; MALE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AUTOCRINE COMMUNICATION; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84923523471     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27624     Document Type: Article

References (20)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
2. Wrzesinski SH, Taddei TH, Strazzabosco M. Systemic therapy in hepatocellular carcinoma. Clin Liver Dis 2011;15:423-441.
3. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012;13:616-630.
4. Derynck R, Akhurst RJ, Balmain A. TGF-beta signalling in tumour suppression and cancer progression. Nat Genet 2001;29:117-129.
5. Heldin CH, Moustakas A. Role of Smads in TGFβ signaling. Cell Tissue Res 2012;347:21-36.
6. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178-196.
7. Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch W, et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc Natl Acad Sci USA 1992;89:5408-5412.
8. Sánchez A, Alvarez AM, Benito M, Fabregat I. Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: involvement of reactive oxygen intermediates. J Biol Chem 1996;271:7416-7422.
9. Im YH, Kim HT, Kim IY, Factor VM, Hahm KB, Anzano M, et al. Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis. Cancer Res 2001;61:6665-6668.
10. Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, Kiso S, et al. Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 1991;51:4080-4083.
11. Factor VM, Kao CY, Santoni-Rugiu E, Woitach JT, Jensen MR, Thorgeirsson SS. Constitutive expression of mature transforming growth factor β1 in the liver accelerates hepatocarcinogenesis in transgenic mice. Cancer Res 1997;57:2089-2095.
12. Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 2008;47:1557-1566.
13. Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 2009;50:1140-1151.
14. Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008;47:2059-2067.
15. Reichl P, Dengler M, van Zijl F, Huber H, Fuhrlinger G, Reichel C, et al. Signaling of Axl via 14-3-3zeta activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma. Hepatology 2015;61:930-941.
16. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008;100:35-83.
17. Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 2011;30:1229-1240.
18. Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B. AXL kinase as a novel target for cancer therapy. Oncotarget 2014;5:9546-9563.
19. Matsuzaki K. Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis 2011;32:1578-1588.
20. Giannelli G, Villa E, Lahn M. Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma. Cancer Res 2014;74:1890-1894.